Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- PMID: 25428504
- PMCID: PMC4836193
- DOI: 10.1038/nature14011
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Abstract
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing tumours to be recognized as foreign by the immune system. However, tumours are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment. Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are negative regulators of T-lymphocyte activation. Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumour cell killing. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections. Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy. This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A. Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumours, version 1.1) were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune cells. Furthermore, responses were associated with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens. Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.
Trial registration: ClinicalTrials.gov NCT01375842.
Figures
Similar articles
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904. Nature. 2014. PMID: 25428503 Clinical Trial.
-
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041
-
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427729
-
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Med Mol Morphol. 2017. PMID: 28936553 Review.
-
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Mol Cancer. 2018 Aug 23;17(1):129. doi: 10.1186/s12943-018-0864-3. Mol Cancer. 2018. PMID: 30139382 Free PMC article. Review.
Cited by
-
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.J Immunother Cancer. 2024 Oct 2;12(10):e009710. doi: 10.1136/jitc-2024-009710. J Immunother Cancer. 2024. PMID: 39357981 Free PMC article.
-
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.Biomedicines. 2024 Sep 23;12(9):2158. doi: 10.3390/biomedicines12092158. Biomedicines. 2024. PMID: 39335671 Free PMC article. Review.
-
New Advances in the Study of CMTM6, a Focus on Its Novel Non-Canonical Cellular Locations, and Functions beyond Its Role as a PD-L1 Stabilizer.Cancers (Basel). 2024 Sep 11;16(18):3126. doi: 10.3390/cancers16183126. Cancers (Basel). 2024. PMID: 39335098 Free PMC article.
-
Research progress and challenges of the PD-1/PD-L1 axis in gliomas.Cell Biosci. 2024 Sep 27;14(1):123. doi: 10.1186/s13578-024-01305-6. Cell Biosci. 2024. PMID: 39334448 Free PMC article. Review.
-
Decoding functional impact of epigenetic regulator mutations on ligand-receptor interaction perturbations for evaluation of cancer immunotherapy.J Cell Mol Med. 2024 Sep;28(18):e70009. doi: 10.1111/jcmm.70009. J Cell Mol Med. 2024. PMID: 39323009 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous